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Abstract
Background: Protein kinases are a large and diverse family of enzymes that are genomically altered in many human cancers.
Targeted cancer genome sequencing efforts have unveiled the mutational profiles of protein kinase genes from many
different cancer types. While mutational data on protein kinases is currently catalogued in various databases, integration of
mutation data with other forms of data on protein kinases such as sequence, structure, function and pathway is necessary
to identify and characterize key cancer causing mutations. Integrative analysis of protein kinase data, however, is a
challenge because of the disparate nature of protein kinase data sources and data formats.
Results: Here, we describe ProKinO, a protein kinase-specific ontology, which provides a controlled vocabulary of terms,
their hierarchy, and relationships unifying sequence, structure, function, mutation and pathway information on protein
kinases. The conceptual representation of such diverse forms of information in one place not only allows rapid discovery of
significant information related to a specific protein kinase, but also enables large-scale integrative analysis of protein kinase
data in ways not possible through other kinase-specific resources. We have performed several integrative analyses of
ProKinO data and, as an example, found that a large number of somatic mutations (,288 distinct mutations) associated
with the haematopoietic neoplasm cancer type map to only 8 kinases in the human kinome. This is in contrast to glioma,
where the mutations are spread over 82 distinct kinases. We also provide examples of how ontology-based data analysis
can be used to generate testable hypotheses regarding cancer mutations.
Conclusion: We present an integrated framework for large-scale integrative analysis of protein kinase data. Navigation and
analysis of ontology data can be performed using the ontology browser available at: http://vulcan.cs.uga.edu/prokino.
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Introduction
Cancer is caused by an accumulation of mutations, often in a
subset of genes that confer survival and growth advantage. The
protein kinase gene family, which controls key signaling pathways
associated with cell growth and survival, is one of the most over-
represented families of oncogenes [1]. Targeted sequencing of 518
protein kinase exons encoded in the human genome (collectively
called the kinome) has revealed hundreds of mutations in the
protein kinase domain [2]. Although these mutations are currently
catalogued in various databases [3,4,5], identification and
experimental characterization of key cancer-causing mutations is
essential for developing new therapies for cancer.
Experimental characterization of cancer mutations, however,
requires that one first formulate the right hypotheses based on
analysis of existing data. In particular, analysis of mutation data in
light of other forms of data available on protein kinases such as
sequence, structure, function and pathway is necessary to develop
and test new hypotheses regarding the functional impact of cancer
mutations [6,7,8,9]. Integrative analysis of protein kinase data,
however, is a challenge because of the disparate nature of protein
kinase data sources and formats. For example, a researcher
interested in the structural location of a cancer mutation, or
distribution of kinase mutations in various cancer types, has to go
through the time-consuming and error prone process of collecting
and parsing data from disparate sources, often in different data
formats. Although several kinase-specific resources such as
KinBase [10], KING [11], PKR [12] and KinMutBase [4] have
been developed, these resources largely focus on one, or few types,
of protein kinase data (e.g., sequence, structure, or mutation),
leaving aside the challenge of data integration.
Ontologies [13] have emerged as a powerful tool for integrative
and quantitative analysis of biological data [14,15,16,17]. By
capturing domain knowledge in the form of concepts (classes) and
relationships, ontologies provide a conceptual representation of
data in a way that computers can read and humans can
understand. For example, for an automated and informed
response to the query ‘‘kinase mutations associated with cancer
types’’, the computer needs to understand the concepts, ‘‘kinase
mutations’’ and ‘‘cancer types’’, and the relationships between the
concepts, namely, ‘‘associated with’’. It is this conceptual represen-
tation of knowledge that distinguishes ontologies from relational
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data sets [18]. Indeed, several ontologies have been developed to
capture and mine the wealth of information on genes (GO) [19],
sequence [20], pathways (http://rgd.mcw.edu/tools/ontology/
ont_search.cgi), protein modification [21] and others [20,22].
Focused ontologies on selected protein families such as the protein
phosphatase family and transporter family have also been
developed [23]. However, up until now, a focused ontology
capturing the state of knowledge on the protein kinase family has
not been reported.
Here, we report the Protein Kinase Ontology (ProKinO).
ProKinO provides a controlled vocabulary of terms and
relationships connecting sequence, structure, function, pathway,
and mutation data on protein kinases. ProKinO is encoded using
the Web Ontology Language (OWL) (http://www.w3.org/TR/
owl-ref/), an ontology authoring language recommended by the
World Wide Web Consortium (http://www.w3.org/). The
integration of diverse data sets in a machine-readable format not
only allows navigation of diverse forms of protein kinase data in
one place, but also enables aggregate queries on existing data in
ways not possible through existing kinase-specific resources. For
example, aggregate queries such as ‘‘counts of kinases associated
with cancer type’’ or ‘‘counts of cancer mutations located in
various kinase sub-domains’’ can be readily performed using
ProKinO and the ontology query language SPARQL (http://
www.w3.org/TR/rdf-sparql-query/). We describe the significance
of such queries in knowledge discovery and hypothesis generation.
An aggregate query ‘‘counts of kinase mutations in various cancer
types’’, for example, revealed that the mutations associated with
haematopoietic neoplasm (288 distinct mutations) primarily target only
8 kinases in the human kinome, compared to glioma, where the
mutations are spread over 82 distinct kinases. Likewise, queries
such as ‘‘mutations targeting kinase functional features’’ can be
used to generate new hypotheses regarding the structural and
functional impact of cancer mutations. We also describe a browser
that enables rapid navigation and examination of ProKinO data,
accessible at: http://vulcan.cs.uga.edu/prokino.
Methods
ProKinO Knowledge Organization
To conceptualize the wealth of knowledge regarding protein
kinase sequence, structure, function, pathways and diseases, we
have introduced several key concepts (classes) and relationships
(object properties) in ProKinO. These classes, organized in a
hierarchical manner, and the relationships amongst these classes,
represent and describe protein kinase knowledge in a manner
analogous to a domain expert.
For example, a kinase expert describing a particular mutation
would describe the mutation in the context of the gene in which
the mutation is found, the kinase encoded by the gene, the group
or family the kinase belongs to, the kinase sub-domain the
mutation is located in, and the pathways in which the mutated
gene participates. The ProKinO schema has been designed to
capture and integrate protein kinase knowledge using the terms
and relationships similar to those typically used by an expert
(Figure 1). For example, the relationship between the ‘‘Gene’’ and
‘‘Mutation’’ classes is described by the ‘‘hasMutation’’ property
(Figure 1), while the ‘‘locatedIn’’ property captures the relationship
between the ‘‘Mutation’’ and ‘‘SubDomain’’ classes. Similarly, the
sequence a kinase belongs to is represented by the ‘‘hasSequence’’
property between the ‘‘Gene’’ and ‘‘Sequence‘‘ classes, and the
sub-domains associated with a particular sequence is conceptual-
ized by the ‘‘hasSubDomain’’ relationship (Figure 1). The pathway
and reaction information related to kinases is conceptualized by
the ‘‘participatesIn’’ relationship between ‘‘Gene’’ and ‘‘Pathway’’,
and ‘‘hasReaction’’ between ‘‘Pathway’’ and ‘‘Reaction’’. To cross
reference ProKinO data to external databases and sources, the
‘‘DbXref’’ class and ‘‘hasDbXref’’ relationship have been intro-
duced (see Figure 1).
The rationale behind representing protein kinase data in the
above described way is that it provides context for interpreting
mutation data. This can be illustrated using the missense mutation
p.L858M in EGFR (Figure 1). p.L858M is a mutation in EGFR
kinase having the type ‘‘Missense’’. The mutation is implicated in
cancer carcinoma and located in the sub domain VII, which
corresponds to the N-terminus of the Activation segment (denoted
as Activation-Segment-NT in Figure 1). The protein encoded by the
EGFR gene participates in a pathway Signaling by EGFR, which
includes EGFR dimerization as one of its reactions. Other classes and
sub-classes are likewise connected to the mutation p.L858M via the
relationships described in Figure 1, providing an integrated view of
all data that would be required to provide structural and functional
context for the p. L858M mutation.
In addition to the major classes and object properties described
above, several additional sub-classes and object properties have
been defined in ProKinO to fully capture and represent the
available knowledge on protein kinase sequence, structure,
function and disease. For example, the sub-classes of the
‘‘Mutation’’ class — ‘‘ComplexMutation’’, ‘‘DeletionMutation’’,
‘‘InsertionMutation’’, ‘‘SubstitutionMutation’’ and ‘‘OtherMuta-
tion’’ — capture information on the types of mutations identified
in kinases. Likewise, the three sub-classes under the ‘‘Functional-
Feature’’ class — ‘‘ModifiedResidue’’, ‘‘TopologicalDomain’’,
‘‘SignalPeptide’’ — capture information on the specific functional
features. This hierarchal organization of classes in ProKinO is
shown in Figure 1.
In addition to the object properties, key data properties have
been introduced to describe the internal organization of the
concepts and to facilitate data mining and extraction. For
example, the data property, ‘‘hasOtherName’’, stores the other
names by which a gene may be known in the literature (synonyms).
For instance, EGFR is also referred as EGFRvIII, ERBB1, ERBB,o r
mENA in the literature. By including the ‘‘hasOtherName’’ data
property, all information pertinent to EGFR can be obtained
irrespective of which gene name is used as a query.
With a large set of classes and properties related to kinases in the
designed schema (refer to Figure S1 for the full schema), ProKinO,
represents an explicit conceptualization and organization of the
knowledge about human protein kinases. ProKinO currently
contains 351 classes, 25 object properties and 27 data properties
(Tables S1, S2 and S3 for full list) capturing information on
protein kinase sequence, structure, function, pathway and disease.
ProKinO Population
ProKinO has been populated with data from data sources that
are well curated and maintained. The acquired data has been
stored as instances in the schema described above (Figure 1).
Data acquisition and storage
Sequence. Data regarding protein kinase sequence and
classification have been obtained from KinBase [10], the
repository for kinase sequence and classification. The 538 kinase
genes currently identified in the human genome have been
classified into major groups and families based on sequence
similarity within the kinase domain. Since the KinBase
classification is widely accepted by the kinase community, we
have adopted the same classification scheme in ProKinO. The
Protein Kinase Ontology
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KinBase includes the extraction, integration and population of
information from 538 human protein kinases and their
classification into various groups, families and subfamilies.
Information regarding gene names, synonyms and chromosomal
position is also obtained from KinBase. The acquired knowledge is
populated as the instances of the ‘‘ProteinKinaseDomain’’ class,
which is further categorized into groups, families, and sub-families
as subclasses. Further, the sequence data of protein kinase genes in
FASTA format has been extracted and populated as instances of
the ‘‘Sequence’’ class.
Function. Information regarding functional domains and
functional features associated with kinase domains have been
obtained from UniProt [24], a curated resource for protein
functional information. Information on the regulatory domains
associated with kinase domains, crystal structures solved for each
kinase, isoforms identified for kinases, modified residue, signal
peptide, topological domain, cellular location and tissue specificity is
also obtained from UniProt. Functional domains related to protein
kinases are populated as instances of the ‘‘FunctionalDomain’’ class,
and cross referenced to Pfam[25], a protein family database, via the
‘‘DBxRef’’ class. Similarly, information about crystal structures is
populated as instances of the ‘‘Structure’’ class with cross references
to the Protein Data Bank (PDB) [26]. Functional feature
information is stored as instances in the ‘‘FunctionalFeature’’
class, with sub-classes based on the type of feature such as
‘‘ModifiedResidue’’, ‘‘TopologicalDomain’’ and ‘‘SignalPeptide’’.
Disease. Although protein kinases have been associated with
several human diseases, the current version of ProKinO primarily
focuses on cancer. Information regarding cancer mutations is
obtained from COSMIC [3], which is one of the oldest and
curated resources for storing information on somatic acquired
mutations associated with human cancers. In addition to
mutations, other information such as primary sites, primary
histology, samples, description and other relevant features have
also been obtained and stored as instances in the ‘‘Mutation’’ class.
The ‘‘Mutation’’ class is specialized further into sub-classes based
on the type of mutation, namely, complex, deletion, insertion,
substitution and other. References to PubMed, MEDLINE and
COSMIC databases are provided in the ‘‘DbXref’’ class.
Pathway. PathwaydataisobtainedfromReactome,amanually
curated and peer-reviewed pathway resource [27]. Pathways and
reaction are stored as instances in the ‘‘BiochemicalEvent’’ class. For
t h es a k eo fc l a r i t y ,w eh a v ea d o p t e dt h es a m et e r m s / c o n c e p t su s e di n
Figure 1. A section of the Protein Kinase Ontology (ProKinO) schema showing key concepts and relationships. The figure shows
concepts (classes) organized in a class sub-class hierarchy (shown as ovals). The relationships (object properties) between classes are shown as red
colored lines. The internal specifics (data properties) of classes are shown as brown colored lines. The instances of classes are shown as rectangles.
The complete ontology schema can be accessed from the ProKinO web site, and also provided as Figure S1.
doi:10.1371/journal.pone.0028782.g001
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a concept used in both Reactome and ProKinO to represent
biological processes that convert input entities to output entities.
‘‘Pathway’’ and ‘‘Reaction’’ are sub-classes under
‘‘BiochemicalEvent’’ (Figure 1). For example, Signaling by EGFR is
an instance in the ‘‘Pathway’’ class, which is related to the ‘‘Reaction’’
class by the ‘‘hasReaction’’ property (Figure 1). The ‘‘Reaction’’ class
has several reactions for a given pathway. EGFR dimerization is one of
the reactions in the Signaling by EGFR pathway (Figure 1). This
reaction ‘‘consumes’’ a complex named EGF:EGFR [plasma membrane],
and ‘‘produces’’ ac o m p l e x ,EGF:EGFR dimer [plasma membrane].B o t h
complexes are stored as members of the ‘‘Complex’’ class.
Kinase Sub-domains. To provide structural context for
cancer mutations, we have incorporated sub-domain information
in ProKinO. Sub-domains correspond to the core conserved
motifs/structural elements that define the kinase catalytic domain
[28]. The sub-domain notation is widely used to describe the
structural organization of motifs and regulatory segments that
make up the catalytic domain. Currently, sub-domain information
on human kinases is not available from any public resource. The
protein kinase resource (PKR) provides sub-domain information
on some (18 kinases), but not on all kinases. To capture the sub-
domain information in ProKinO, we have used a motif model,
which captures key motifs corresponding to each of XII sub-
domains in the kinase domain [6,29]. The motif model was run
against all UniProt and COSMIC sequences to identify the start
and end location of sub-domains in sequences. The start and end
locations of sub-domains have been stored in ProKinO as
instances in the ‘‘SubDomain’’ class. Because sub-domain
boundaries are difficult to delineate for divergent protein
kinases, such as the atypical kinases, the sub-domain class is not
populated for all protein kinases.
Automation of data acquisition and updates
We have created a specialized software system to automatically
populate ProKinO from the above described sources. The
software is written using the Java programming language. The
software performs all of the required functions for ontology
creation and automatic population, including data acquisition,
parsing and processing, as well as the creation of instances and
connections among them using the relationships defined in the
ProKinO schema. The populated ontology is encoded and output
in OWL, an ontology authoring and sharing language recom-
mended by the World Wide Web Consortium. Our software also
uses Jena, a widely used Java-based Application Programming
Interface (API) (http://jena.sourceforge.net/) for parsing, creating
and querying Resource Description Framework (RDF) (http://
www.w3.org/RDF/) and OWL ontologies.
The ontologies, and hence any software applications and
resources utilizing them, are bound to evolve with time. ProKinO
integrates knowledge from disparate sources without modifying
any of the original data. Therefore, any changes in the data
sources used in ProKinO creation require the corresponding
changes in the ontology to assure that it is up-to-date and
consistent. The sources of knowledge used in ProKinO are subject
to frequent modifications and are updated on a regular basis. For
instance, UniProt is updated every three weeks and COSMIC
approximately every two months. For the knowledge integrated in
the ontology to be current and consistent with the existing data
available in the parent sources, ProKinO will be updated by our
automatic population process on a regular basis, as well. The
version information about all data sources used to populate
ProKinO will be included, as well. To assure that the needs of user
community are satisfied, any needed schema modifications and
extensions will be introduced in new ProKinO versions at
appropriate times. All of the versions of ProKinO will be archived
along with the information about differences between versions.
The ontology lifecycle will be tracked by a versioning system [30],
and any prior versions of ProKinO will be easily accessible.
Results and Discussion
ProKinO Evaluation
Because the ontology development process is costly and time
consuming, careful evaluation of ontology content is necessary to
determine its suitability in serving the intended purpose of its
development. ProKinO has been evaluated for its accuracy and
usefulness. We have used two approaches to evaluate the accuracy
of ProKinO content: (i) a manual approach in which a set of
instances and relationships among them are randomly selected
and cross-checked with content from original sources, and (ii) a
query-based approach in which ontology data is queried for
information that can easily be cross validated with data from
original sources.
Manual Approach. In the manual approach, the test sets
were chosen to evaluate a broad coverage of the ontology content.
The accuracy of the data was checked by cross validating with the
original data sources. The integration of the data in ProKinO was
also verified by evaluating the introduced object and data
properties for accuracy. For example, EGFR kinase’s relationship
with pathways represented as a property ‘‘partcipatesIn’’ was verified
for accuracy by cross validating the content in ProKinO with the
original data available in Reactome. Our verification has not
detected any errors in ProKinO. The details of the evaluation are
shown in Table S4.
Query-based Approach. In addition to the manual
approach, a query-based approach was used to verify the
content of the ontology. The SPARQL query language was used
to perform the queries. For example, the query ‘‘count of crystal
structures for all protein kinases’’ resulted in 200 hits for Cdk2
(Figure 2). This result was cross-validated by checking the Cdk2
‘‘PDB’’ entry in UniProt. Similarly, the query ‘‘count of isoforms
for all protein kinases’’ resulted in 20 hits for FGFR2 and 19 for
FGFR1 (Figure 3). This was cross-validated by checking for FGFR1
and FGFR2 isoform entries in UniProt. Likewise, ‘‘counts of
kinases associated with pathways’’ resulted in 11 pathways for
SRC, and 10 for PKACA (PRKACA in Reactome). This result was
also cross-validated with the original source, i.e. Reactome
(Figure 4). Similarly, ‘‘counts of kinases implicated in various
cancer types’’ resulted in the most number of hits for BRAF (30
cancer types) (Figure 5), which was cross-validated from the
COSMIC database.
ProKinO Application
The compendium of knowledge represented in ProKinO can be
used for a variety of applications such as data mining, text mining
and genome annotation. In particular, the representation of
diverse protein kinase data in machine-readable form enables
complex aggregate queries on ontology data, in ways not possible
through existing kinase-specific resources. Below, we describe
some of these queries to illustrate how ProKinO data can be used
for knowledge discovery and hypothesis generation. The queries,
which have been formulated in SPARQL, also provide an initial
evaluation of ProKinO’s usefulness.
Query 1. The SPARQL queries ‘‘counts of substitution
missense mutations in cancer types’’, and ‘‘counts of protein
kinases having missense mutations’’ was performed on ProKinO to
analyze the distribution of kinase mutations in various cancer
Protein Kinase Ontology
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the distribution of kinase mutations is strikingly different for
different cancer types (Figure 6). In particular, carcinoma (1168
mutations), glioma (180), malignant melanoma (201), haematopoietic
neoplasm (288), and lymphoid neoplasm (164) are highly over-
represented in kinase mutations compared to other cancer types
(Figure 6). Furthermore, the 288 and 164 mutations associated
with haematopoietic neoplasm and lymphoid neoplasm map to only 8 and
12 kinases, respectively. This is in contrast to glioma, where the
mutations are spread over 82 distinct kinases. While this finding
could result from the bias in the sequencing of cancer kinomes
from selected cancer types, it is also possible that only a few
signaling pathways (associated with the 8 kinases) are altered in
haematopoietic neoplasm, compared to glioma. Such observations have
Figure 2. Counts of crystal structures of all protein kinases. Top ten kinases in the descending order of counts are displayed. The Y-axis shows
the number of structures solved for each of ten over-represented kinases. Structures solved with inhibitors were included in the total count. X-axis
denotes the kinase names. Aurora kinase is labeled as AURA. The SPARQL query used to generate this figure can be viewed and excuted from the
ProKinO browser by selecting ‘‘Query 1’’ under the ‘‘Example queries’’ tab in the main page.
doi:10.1371/journal.pone.0028782.g002
Figure 3. Counts of isoforms for all protein kinases. Top 10 kinases are displayed in descending order of their values. The Y-axis shows the
number of validated isoforms for each of the kinass. The SPARQL query used to generate this figure can be viewed and excuted from the ProKinO
browser by selecting ‘‘Query 2’’ under the ‘‘Example queries’’ tab in the main page.
doi:10.1371/journal.pone.0028782.g003
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generating new hypotheses for experimental studies.
Query 2. Based on the observation from Query 1, additional
SPARQL queries can be performed to obtain further information
on the 8 kinases associated with haematopoietic neoplasm. For
example, the query requesting for the ‘‘counts of protein kinases
having missense mutations in haematopoietic neoplasm’’ indicates that
ABL1, KIT, FLT3 and JAK2 are more frequently mutated
Figure 4. Counts of number of pathways associated with all protein kinases. Top 10 kinases with the most number of pathways are
displayed in descending order. The SPARQL query to generate this figure can be directly viewed and excuted from the ProKinO browser by selecting
‘‘Query 3’’ under the ‘‘Example queries’’ tab in the main page.
doi:10.1371/journal.pone.0028782.g004
Figure 5. Counts of different cancer types implicated in protein kinases. Top ten kinases are in descending order of their values. The
SPARQL query to generate this figure can be directly viewed and excuted from the ProKinO browser by selecting ‘‘Query 4’’ under the ‘‘Example
queries’’ tab in the main page.
doi:10.1371/journal.pone.0028782.g005
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consistent with the findings reported in the literature [31,32],
further cross-validating the contents of the ontology.
Query 3. Query 2 (above) can be further refined to obtain
testable hypotheses regarding cancer mutations. For example,
queries requesting functional features and sub-domain location for
Figure 6. Counts of substitution missense mutations (at least 4) implicated in different types of cancer, and counts of protein
kinases having missense mutations implicated in different cancer types. As mentioned in the text, haematopoietic_neoplasm has 288
mutations in 8 kinases, while glioma has 180 mutations spread over 82 kinases. The SPARQL query to generate this figure can be directly viewed and
excuted from the ProKinO browser by selecting ‘‘Query 5a’’ and ‘‘Query 5b’’ under the ‘‘Example queries’’ tab in the main page.
doi:10.1371/journal.pone.0028782.g006
Figure 7. Counts of protein kinases having missense mutations implicated in haematopoietic neoplasm. Top 10 hits in descending
order of the counts are displayed. The SPARQL query to generate this figure can be viewed and excuted from the ProKinO browser by selecting
‘‘Query 6’’ under the ‘‘Example queries’’ tab in the main page.
doi:10.1371/journal.pone.0028782.g007
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Y253F is located in the functionally important Glycine rich loop (Sub-
domain I; Table S5), and has modified residues property
‘‘Phosphotyrosine’’. With this information, one can formulate a
testable hypothesis that ‘‘Y253F mutation contributes to abnormal
ABL1 functions by altering the phosphorylation status of the
glycine rich loop’’.
In addition to the queries described above, we have formulated
several additional queries on ProKinO. The results obtained from
these queries are provided as supplementary figures (see Figures
S2, S3, S4, S5, S6, S7, S8, S9). The SPARQL queries themselves
are provided in Figure S10.
Future Directions
ProKinO is an ontology of terms and relationships capturing the
state of knowledge on the protein kinase family. Representation of
protein kinase knowledge in the form of ontology allows effective
mining and systems-level analysis of protein kinase data, as
demonstrated through several SPARQL queries. To enable
navigation and integrative analysis of ontology data, an ontology
browser has been developed. The browser can be accessed from
http://vulcan.cs.uga.edu/prokino.
While the current version of ProKinO largely focuses on human
protein kinase genes, information on other model organisms can
be incorporated in ProKinO through the addition of new classes
and data properties in the ontology schema. Likewise, the wealth
of information generated on protein kinase substrates through
high-throughput phospho-proteomic data can be incorporated to
integrate cancer data with proteomics data. Furthermore, we
anticipate ProKinO to be useful in providing consistent annotation
of mutations identified in cancer genome sequencing studies.
Using specific queries we have demonstrated how data in the
ontology can be used to generate new hypotheses regarding the
structural and functional impact of mutations. In particular, the
observation that nearly 288 mutations map to only eight kinases in
haematopoietic neoplasm is novel and provides new hypotheses for
follow-up studies. Likewise, the prediction that Y253F mutation
alters the phosphorylation status of the glycine rich loop in ABL
tyrosine kinase can be tested experimentally. The SPARQL
queries described in this study can be executed from the browser
by selecting the ‘‘Example queries’’ tab in the main page.
In the near future, we are planning to submit ProKinO to be
included in The Open Biological and Biomedical Ontologies
(OBO) foundry (http://www.obofoundry.org/), after introducing
necessary changes to make ProKinO conformant to OBO
guidelines. Similarly, we plan to make it available through NCBO
BioPortal (http://bioportal.bioontology.org/). We also intend to
continue the study of the applicability of ProKinO to other
bioinformatics tasks, including text mining of bio-medical scientific
literature, genome annotation, and others.
Supporting Information
Figure S1 Conceptual schema of the Protein Kinase
Ontology (ProKinO) showing concepts and relationships
representing protein kinase knowledge. The high resoulu-
tion image of the schema is also available from the main page of
ProKinO browser.
(PDF)
Figure S2 Plot showing counts of different mutations (of
all types) for all kinase genes. Top 10 hits are displayed in
the descending order of their values. Notably, KIT and EGFR are
the two of the most frequently mutated kinases in human cancers.
The SPARQL query to generate this figure can be directly viewed
and excuted from the ProKinO browser by selecting ‘‘Query 7’’
under the ‘‘Example query’’ tab in the main page.
(PDF)
Figure S3 Plot showing counts of substitution missense
mutations for all genes. Top 10 hits are displayed in
descending order of their values. It should be noted that while
the total number of mutations is higher for KIT (Figure 2),
counting only the missense mutations reveals higher number of
mutations for EGFR compared to KIT. The SPARQL query to
generate this figure can be directly viewed and excuted from the
ProKinO browser by selecting ‘‘Query 8’’ under the ‘‘Example
query’’ tab in the main page.
(PDF)
Figure S4 Plot showing counts of protein kinases (at
least 2) having mutations (of any type) implicated in
different types of cancer. Kinases are displayed in descending
order of the counts. The SPARQL query to generate this figure
can be directly viewed and excuted from the ProKinO browser by
selecting ‘‘Query 9’’ under the ‘‘Example query’’ tab in the main
page.
(PDF)
Figure S5 Plot showing counts of protein kinases (at
least 4) participating in pathways. Hits are display in
descending order of their values; include only pathways with 4 or
more participating kinases. Notably, most of the mutated kinases
appear to target pathways associated with the immune system, as
indicated by high counts for ‘‘signaling in immune system’’
pathway. The SPARQL query to generate this figure can be
directly viewed and excuted from the ProKinO browser by
selecting ‘‘Query 10’’ under the ‘‘Example query’’ tab in the main
page.
(PDF)
Figure S6 Plot showing counts of pathways in which
mutated protein kinases participate. Hits are displayed in
descending order of their values. Kinases that participate in 4 or
more pathways are included. The SPARQL query to generate this
figure can be directly viewed and excuted from the ProKinO
browser by selecting ‘‘Query 11’’ under the ‘‘Example query’’ tab
in the main page.
(PDF)
Figure S7 Plot showing counts of protein kinases having
mutations (of any type) in various primary sites. Hits are
displayed in descending order of their values. Notably, most
number of mutated kinases are implicated in the cancers of lung
and the central nervous system. The SPARQL query to generate
this figure can be directly viewed and excuted from the ProKinO
browser by selecting ‘‘Query 12’’ under the ‘‘Example query’’ tab
in the main page.
(PDF)
Figure S8 Plot showing counts of different mutations
(all types) for all sub-domains. Notably, the flanking N and
C-terminal tail segment harbor significant number of mutations,
followed by the regulatory activation segment and C-helix in the
kinase domain. The SPARQL query to generate this figure can be
directly viewed and excuted from the ProKinO browser by
selecting ‘‘Query 13’’ under the ‘‘Example query’’ tab in the main
page.
(PDF)
Figure S9 Plot showing counts of substitution missense
mutations of the protein kinase FLT3 all having the
primary site of Haematopoietic and Lymphoid tissue,
Protein Kinase Ontology
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28782and located in various sub-domains. Notably, the activation
segment has the most number of mutations. The SPARQL query
to generate this figure can be directly viewed and excuted from the
ProKinO browser by selecting ‘‘Query 14’’ under the ‘‘Example
query’’ tab in the main page.
(PDF)
Figure S10 SPARQL queries for the main (Figures 2, 3,
4, 5, 6, 7) and supplementary (figures S2, S3, S4, S5, S6,
S7, S8, S9) figures described in this study.
(PDF)
Table S1 Classes (concepts) in ProKinO.
(DOC)
Table S2 Object properties used in ProKinO.
(DOC)
Table S3 Data properties used in ProKinO.
(DOC)
Table S4 ProKinO evaluation statistics.
(DOC)
Table S5 Protein kinases implicated in Haematopoietic
and lymphoid_tissue and having modified residue type
property.
(DOC)
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